- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | TETRATHERIX LIMITED: Details of Auditor Appointment/Resignation | - | ASX | ||
| Do | TETRATHERIX LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| Do | TETRATHERIX LIMITED: TegenEOS Biologic Pathway | 1 | ASX | ||
| 21.10. | TETRATHERIX LIMITED: Notification of cessation of securities - TTX | 1 | ASX | ||
| 21.10. | TETRATHERIX LIMITED: Application for quotation of securities - TTX | - | ASX | ||
| TETRATHERIX Aktie jetzt für 0€ handeln | |||||
| 12.10. | TETRATHERIX LIMITED: Notice of Annual General Meeting/Proxy Form | 2 | ASX | ||
| 07.10. | TETRATHERIX LIMITED: Application for quotation of securities - TTX | 1 | ASX | ||
| 05.10. | TETRATHERIX LIMITED: Tegenix FDA Review Progress | - | ASX | ||
| 02.10. | TETRATHERIX LIMITED: Notification regarding unquoted securities - TTX | - | ASX | ||
| 16.09. | TETRATHERIX LIMITED: Line of sight ophthalmic tissue spacing US revenue | 1 | ASX | ||
| 31.08. | TETRATHERIX LIMITED: Tetratherix Ships First US Polymer, Revenue Begins | 3 | ASX | ||
| 24.08. | TETRATHERIX LIMITED: Application for quotation of securities - TTX | - | ASX | ||
| 20.08. | TETRATHERIX LIMITED: Results Presentation 2026 | 1 | ASX | ||
| 20.08. | TETRATHERIX LIMITED: Appendix 4E and Annual Report 2026 | 1 | ASX | ||
| 22.07. | TETRATHERIX LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 01.07. | TETRATHERIX LIMITED: Notification regarding unquoted securities - TTX | - | ASX | ||
| 23.06. | TETRATHERIX LIMITED: Tutela Interim Study Results | 1 | ASX | ||
| 23.06. | TETRATHERIX LIMITED: Application for quotation of securities - TTX | - | ASX | ||
| 22.06. | TETRATHERIX LIMITED: SPP Results | - | ASX | ||
| 19.06. | TETRATHERIX LIMITED: Application for quotation of securities - TTX | - | ASX |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,090 | +0,09 % | Qiagen zieht an, Siemens Energy schmiert ab: DAX-Ausblick | Der DAX ist in der vergangenen Woche wieder deutlich zurückgefallen. Unter dem Strich büßte das größte deutsche Börsenbarometer 440 Punkte ein und schloss -1,72% tiefer mit 25.181 Punkten. Die höchsten... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,020 | 0,00 % | Stifel bekräftigt Kaufempfehlung für Cogent Biosciences nach ESMO-Daten | ||
| ENLIVEN THERAPEUTICS | 44,250 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year | Accomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readiness
Enliven continues preparation for late-stage... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 18,155 | -0,14 % | Mineralys Therapeutics, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 126,72 | +0,07 % | Oppenheimer raises Kymera Therapeutics price target on drug data | ||
| TANGO THERAPEUTICS | 22,710 | 0,00 % | Tango Therapeutics (TNGX) vs. CRSP and SMMT: Can Vopimetostat Turn Promising Cancer Data Into an 89% Upside? | ||
| BAMBUSA THERAPEUTICS | 14,900 | -0,60 % | Bambusa Therapeutics, Inc.: Bambusa Therapeutics Announces Pricing of Upsized Initial Public Offering | BOSTON, Oct. 29, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Nasdaq: BBTX) ("Bambusa Therapeutics" or " Bambusa"), a clinical-stage biopharmaceutical company developing next-generation, long-acting... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,025 | -0,12 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| SUMMIT THERAPEUTICS | 16,030 | 0,00 % | Summit Therapeutics: Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China | First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in... ► Artikel lesen | |
| VOR BIOPHARMA | 19,680 | 0,00 % | Vor Bio Down on Q3 Results | ||
| KINIKSA PHARMACEUTICALS | 92,10 | -0,15 % | Goldman Sachs raises Kiniksa stock price target on strong Arcalyst sales | ||
| PRIME MEDICINE | 4,720 | 0,00 % | Prime Medicine, Inc.: Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease | -- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutation... ► Artikel lesen | |
| ERASCA | 14,330 | -0,14 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| ABSCI | 11,125 | -0,04 % | Jefferies nimmt Absci mit "Buy" auf - Potenzial bei Wirkstoff gegen Haarausfall im Fokus | ||
| NURIX THERAPEUTICS | 26,780 | -0,07 % | Nurix Therapeutics Swings To Profit In Q3 On Roche Licensing Revenue | SOUTH SAN FRANCISCO (dpa-AFX) - Nurix Therapeutics, Inc. (NRIX), clinical-stage biopharmaceutical company, reported a swing to profit in the third quarter from a loss in the year-ago period... ► Artikel lesen |
Das Unternehmen TETRATHERIX LIMITED kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TETRATHERIX LIMITED finden Sie auf Wallstreet Online.